Show simple item record

Authordc.contributor.authorMolina, Ramiro C. 
Authordc.contributor.authorSandoval, Jorge Z. 
Authordc.contributor.authorMontero, Adela V. 
Authordc.contributor.authorOyarzún, Pamela G. 
Authordc.contributor.authorMolina, Temístocles G. 
Authordc.contributor.authorGonzález, Electra A. 
Admission datedc.date.accessioned2019-03-11T12:56:54Z
Available datedc.date.available2019-03-11T12:56:54Z
Publication datedc.date.issued2009
Cita de ítemdc.identifier.citationJournal of Pediatric and Adolescent Gynecology, Volumen 22, Issue 1, 2018, Pages 25-31
Identifierdc.identifier.issn10833188
Identifierdc.identifier.other10.1016/j.jpag.2008.07.010
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/164699
Abstractdc.description.abstractStudy Objective: To compare in a regular non-clinical trial experience the efficacy, acceptability, and continuation rates of an injectable contraceptive containing 50 mg norethisterone enanthate plus 5mg estradiol valerate (IC) and an oral contraceptive containing 0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol (OC), among adolescent users. Design: A total of 251 adolescents ages 14-19 were followed during 12 months. The IC group (124 subjects) was studied for 1044 cycles and the OC group (127 subjects) was studied for 1368 cycles. The users were not assigned in a random selection. Information was collected from clinical records. Groups were compared using Pearson chi-square, odds ratio (95% confidence interval), t-test, and proportion difference test. Results: The IC group had significant differences in baseline social risk, confidence, psychiatric problems, consumption of alcohol, and number of sexual partners. At 12 months, the IC group showed significant decrease in weight a
Lenguagedc.language.isoen
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
Sourcedc.sourceJournal of Pediatric and Adolescent Gynecology
Keywordsdc.subjectContraception in high risk adolescents
Keywordsdc.subjectInjectable monthly contraceptive
Títulodc.titleComparative Performance of a Combined Injectable Contraceptive (50 mg Norethisterone Enanthate Plus 5mg Estradiol Valerate) and a Combined Oral Contraceptive (0.15 mg Levonorgestrel plus 0.03 mg Ethinyl Estradiol) in Adolescents
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorSCOPUS
Indexationuchile.indexArtículo de publicación SCOPUS
uchile.cosechauchile.cosechaSI


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile